Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 09, 2017 16:05 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Announces Closing of Public Offering

PHILADELPHIA, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today the closing of the previously announced underwritten public offering of its common...
August 03, 2017 19:18 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Announces Pricing of $350.0 Million Public Offering

PHILADELPHIA, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today the pricing of an underwritten public offering of 4,605,264 shares of its common...
August 02, 2017 17:04 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Announces Proposed Public Offering of Common Stock

PHILADELPHIA, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today that it has commenced an underwritten public offering of $300,000,000 in shares of...
August 02, 2017 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Progress

Preliminary interim data for SPK-8011 Phase 1/2 dose-escalation clinical trial in hemophilia A show initial human proof-of-concept in three participants In the two participants at the initial dose,...
July 31, 2017 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Submits Marketing Authorization Application to European Medicines Agency for Investigational LUXTURNA™ (voretigene neparvovec)

PHILADELPHIA, July 31, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
July 28, 2017 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics to Host Conference Call on Wednesday, Aug. 2 at 8:30 a.m. ET to Discuss Second Quarter 2017 Results

PHILADELPHIA, July 28, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a...
July 20, 2017 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Receives Rare Pediatric Disease Designation for Investigational LUXTURNA™ (voretigene neparvovec) from FDA

PHILADELPHIA, July 20, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
July 17, 2017 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics’ Biologics License Application for Investigational Voretigene Neparvovec Accepted for Filing by FDA

FDA grants Priority Review with Prescription Drug User Fee Act (PDUFA) date of Jan. 12, 2018 LUXTURNATM (voretigene neparvovec) unveiled as proposed trade name PHILADELPHIA, July 17, 2017 (GLOBE...
July 13, 2017 18:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Announces Publication in The Lancet of Pivotal Phase 3 Clinical Trial Data for Investigational Voretigene Neparvovec

PHILADELPHIA, July 13, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
July 10, 2017 11:47 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Presents Updated Interim Hemophilia B Data Supporting Consistent and Sustained Response at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress

Data demonstrate a 99-percent reduction in annualized infusion rate (AIR) and a 96-percent reduction in annualized bleeding rate (ABR) in 10 participants as of June 5, 2017 Five trial participants...